Abstract | PURPOSE: EXPERIMENTAL DESIGN: Clonogenic survival assays and an orthotopic mouse model of HPV(+) oral cancer were used to examine the in vitro and in vivo sensitivity of HPV(+) HNSCC cell lines to AZD-1775 in combination with cisplatin, respectively. Cell-cycle analysis, DNA damage (γH2AX), homologous recombination (HR), and apoptosis were examined to dissect molecular mechanisms. RESULTS: We found that AZD-1775 displays single-agent activity and enhances the response of HPV(+) HNSCC cells to cisplatin both in vitro and in vivo. The sensitivity of the HPV(+) HNSCC cells to AZD-1775 alone or in combination with cisplatin was associated with G2 checkpoint abrogation, persistent DNA damage, and apoptosis induction. This finding of AZD-1775 increasing the sensitivity of HPV(+) HNSCC cells to cisplatin through apoptosis was not seen previously in the HPV(-) HNSCC cancer cells and is accompanied by a decreased expression of the antiapoptotic proteins, MCl-1and XIAP, which appear to be cleaved following AZD-1775 treatment. CONCLUSIONS:
AZD-1775 selectively sensitizes HPV(+) HNSCC cells and orthotopic oral xenografts to cisplatin through apoptosis and support the clinical investigation of AZD-1775 in combination with cisplatin particularly in patients with advanced and recurrent metastatic HPV(+) HNSCC tumors.
|
Authors | Noriaki Tanaka, Ameeta A Patel, Jiping Wang, Mitchell J Frederick, Nene N Kalu, Mei Zhao, Alison L Fitzgerald, Tong-xin Xie, Natalie L Silver, Carlos Caulin, Ge Zhou, Heath D Skinner, Faye M Johnson, Jeffrey N Myers, Abdullah A Osman |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 21
Issue 21
Pg. 4831-44
(Nov 01 2015)
ISSN: 1557-3265 [Electronic] United States |
PMID | 26124202
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | ©2015 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents
- Cell Cycle Proteins
- Myeloid Cell Leukemia Sequence 1 Protein
- Nuclear Proteins
- Protein Kinase Inhibitors
- Pyrazoles
- Pyrimidines
- Pyrimidinones
- X-Linked Inhibitor of Apoptosis Protein
- Protein-Tyrosine Kinases
- WEE1 protein, human
- Caspases
- adavosertib
- Cisplatin
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Carcinoma, Squamous Cell
(etiology, metabolism)
- Caspases
(metabolism)
- Cell Cycle Proteins
(antagonists & inhibitors)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cisplatin
(pharmacology)
- Disease Models, Animal
- Drug Resistance, Neoplasm
(genetics)
- Drug Synergism
- G2 Phase Cell Cycle Checkpoints
(drug effects)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Gene Knockdown Techniques
- Genes, p53
- Head and Neck Neoplasms
(etiology, metabolism)
- Humans
- Inhibitory Concentration 50
- Male
- Mice
- Myeloid Cell Leukemia Sequence 1 Protein
(genetics, metabolism)
- Nuclear Proteins
(antagonists & inhibitors)
- Papillomavirus Infections
(complications, virology)
- Protein Kinase Inhibitors
(pharmacology)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrazoles
(pharmacology)
- Pyrimidines
(pharmacology)
- Pyrimidinones
- Squamous Cell Carcinoma of Head and Neck
- Tumor Burden
(drug effects)
- X-Linked Inhibitor of Apoptosis Protein
(genetics, metabolism)
- Xenograft Model Antitumor Assays
|